Jeffrey Jerome Ludwig Sells 6,051 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Jeffrey Jerome Ludwig sold 6,051 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $3.27, for a total transaction of $19,786.77. Following the transaction, the insider now owns 120,986 shares in the company, valued at $395,624.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Puma Biotechnology Trading Down 5.5 %

Shares of Puma Biotechnology stock traded down $0.18 during trading hours on Tuesday, reaching $3.10. 852,851 shares of the company’s stock were exchanged, compared to its average volume of 542,683. The firm has a market capitalization of $149.54 million, a price-to-earnings ratio of 9.39 and a beta of 1.09. The company has a current ratio of 1.46, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07. Puma Biotechnology, Inc. has a 52-week low of $2.13 and a 52-week high of $7.73. The company has a fifty day moving average of $3.99 and a 200-day moving average of $4.80.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.12. The firm had revenue of $43.80 million during the quarter, compared to the consensus estimate of $41.53 million. Puma Biotechnology had a net margin of 6.79% and a return on equity of 35.49%. Sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.22 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on PBYI. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research note on Monday, June 3rd. StockNews.com raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, June 12th.

Institutional Investors Weigh In On Puma Biotechnology

Several large investors have recently made changes to their positions in PBYI. SG Americas Securities LLC purchased a new position in shares of Puma Biotechnology in the first quarter valued at $57,000. Ritholtz Wealth Management acquired a new position in shares of Puma Biotechnology in the fourth quarter worth about $66,000. Crestline Management LP boosted its holdings in Puma Biotechnology by 6.5% in the fourth quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 2,135 shares during the last quarter. Jump Financial LLC increased its holdings in Puma Biotechnology by 131.7% during the 4th quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 32,510 shares during the last quarter. Finally, Citigroup Inc. acquired a new position in shares of Puma Biotechnology in the 3rd quarter valued at approximately $262,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.